更新于：2024-09-19

LRFN5

更新于：2024-09-19

基本信息

别名

C14orf146、FIGLER8、leucine rich repeat and fibronectin type III domain containing 5

+ [3]

简介

Cell adhesion molecule that mediates homophilic cell-cell adhesion in a Ca(2+)-independent manner. Promotes neurite outgrowth in hippocampal neurons.

关联

100 项与 LRFN5 相关的临床结果

登录后查看更多信息

100 项与 LRFN5 相关的转化医学

登录后查看更多信息

0 项与 LRFN5 相关的专利（医药）

登录后查看更多信息

项与 LRFN5 相关的文献（医药）

2024-01-01·Journal of Affective Disorders

TCF4 and RBFOX1 as peripheral biomarkers for the differential diagnosis and treatment of major depressive disorder

Article

作者: Ren, Yi ; Feng, Jinzhou ; Chen, Jianjun ; Wu, Wentao ; Xie, Peng ; Xu, Ke ; Zhao, Shuang ; Tu, Dianji ; Fan, Li ; Zhong, Qi

BACKGROUNDRecent genome-wide association studies on major depressive disorder (MDD) have indicated the involvement of LRFN5 and OLFM4; however, the expression levels and roles of these molecules in MDD remain unclear. The present study aimed to determine the serum levels of TCF4 and RBFOX1 in patients with MDD and to investigate whether these molecules could be used as biomarkers for MDD diagnosis.METHODSThe study included 99 drug-naïve MDD patients, 90 drug-treated MDD patients, and 81 healthy controls (HCs). Serum TCF4 and RBFOX1 levels were measured by ELISA. Pearson's correlation analysis was conducted to determine the association between TCF4/RBFOX1 and clinical variables. Linear support vector machine classifier was used to evaluate the diagnostic capabilities of TCF4 and RBFOX1.RESULTSSerum TCF4 and RBFOX1 levels were substantially higher in MDD patients than in HCs and significantly lower in drug-treated MDD patients than in drug-naïve MDD patients. Moreover, serum TCF4 and RBFOX1 levels were associated with the Hamilton Depression Scale score, duration of illness, serum lipids levels, and hepatic function. Thus, both these molecules showed potential as biomarkers for MDD. TCF4 and RBFOX1 combination exhibited a higher diagnostic performance, with the mean area under the curve values of 0.9861 and 0.9936 in the training and testing sets, respectively.LIMITATIONSSmall sample size and investigation of only the peripheral nervous system.CONCLUSIONSTCF4 and RBFOX1 may be involved in the pathogenesis of MDD, and their combination may serve as a diagnostic biomarker panel for MDD.

2023-06-06·Translational psychiatry

LRFN5 and OLFM4 as novel potential biomarkers for major depressive disorder: a pilot study.

Article

作者: Chen, Xiangyu ; Zheng, Peng ; Zhang, Hanping ; Chen, Jianjun ; Feng, Jinzhou ; Xu, Ke ; Wang, Jiubing ; Zhong, Qi ; Xie, Peng ; Ren, Yi ; Zhao, Shuang

Evidences have shown that both LRFN5 and OLFM4 can regulate neural development and synaptic function. Recent genome-wide association studies on major depressive disorder (MDD) have implicated LRFN5 and OLFM4, but their expressions and roles in MDD are still completely unclear. Here, we examined serum concentrations of LRFN5 and OLFM4 in 99 drug-naive MDD patients, 90 drug-treatment MDD patients, and 81 healthy controls (HCs) using ELISA methods. The results showed that both LRFN5 and OLFM4 levels were considerably higher in MDD patients compared to HCs, and were significantly lower in drug-treatment MDD patients than in drug-naive MDD patients. However, there were no significant differences between MDD patients who received a single antidepressant and a combination of antidepressants. Pearson correlation analysis showed that they were associated with the clinical data, including Hamilton Depression Scale score, age, duration of illness, fasting blood glucose, serum lipids, and hepatic, renal, or thyroid function. Moreover, these two molecules both yielded fairly excellent diagnostic performance in diagnosing MDD. In addition, a combination of LRFN5 and OLFM4 demonstrated a better diagnostic effectiveness, with an area under curve of 0.974 in the training set and 0.975 in the testing set. Taken together, our data suggest that LRFN5 and OLFM4 may be implicated in the pathophysiology of MDD and the combination of LRFN5 and OLFM4 may offer a diagnostic biomarker panel for MDD.

2023-06-01·Autism research : official journal of the International Society for Autism Research

Locus conversions are rare in the LRFN5 locus.

Letter

作者: Houge, Gunnar ; Sampson, Jacob ; Banka, Siddharth

项与 LRFN5 相关的新闻（医药）

2023-03-28

·药研网

BTLA入局免疫检查点的下一个十年

01BTLA与HVEMB和T淋巴细胞衰减因子(BTLA)是CD28超家族成员，蛋白结构与PD-1和CTLA-4类似。BTLA的细胞外结构域含有一个Ig样V型结构域，与之相连的是跨膜片段，以及含有ITIM和ITSM的细胞质尾部，参与介导抑制信号转导。BTLA结构[1]BTLA在淋巴结、胸腺和脾脏中广泛表达，但在心脏、肾脏、脑和肝脏等器官中表达水平较低。在免疫细胞中，BTLA主要表达于B细胞和T细胞。此外，BTLA在DCs和单核细胞等固有免疫细胞也有表达。虽然初始CD4+和CD8+ T细胞仅表达少量的BTLA，但在T细胞活化后，BTLA表达会迅速上调。2003年，BTLA被华盛顿大学医学院免疫生物学Kenneth Murphy教授首次发现，但彼时，BTLA由于配体未知，并未像PD-1一样风靡全球。2005年，BTLA的特异性配体HVEM（疱疹病毒入侵介质）被发现。HVEM在各种免疫细胞上广泛表达，包括树突状细胞、初始T细胞和B细胞、NK细胞、单核细胞和中性粒细胞。HVEM与BTLA结合会抑制T细胞和B细胞活化、增殖以及细胞因子生成。此外，与初始效应T细胞激活后下调HVEM表达相反，HVEM在受到刺激并与BTLA（在效应 T 细胞上表达）结合后，调节性T细胞上的HVEM表达会上调，从而增强了调节性T细胞的抑制活性。HVEM可以与BTLA以顺式或反式方式相互作用。除BTLA外，HVEM还可以与CD160、LT-α、LIGHT (TNFSF14)和突触黏附样分子5 (SALM5)相互作用。HVEM在调节T细胞中起双重作用，HVEM与BTLA/CD160结合触发共抑制信号，而当HVEM与LIGHT/LTα结合时则传递共刺激信号。因此，HVEM通常被认为是取决于所结合配体的分子开关。 [3]02BTLA在疾病中的作用癌症BTLA表达于肿瘤浸润淋巴细胞(TILs)，常与抗肿瘤免疫应答受损相关。胆囊癌中BTLA表达上调具有抑制抗癌免疫的作用。在肝细胞癌患者中，循环CD4+T细胞的BTLA表达水平显著高于CD8+T细胞。此外，弥漫性大B细胞淋巴瘤、肺癌和黑色素瘤患者的T细胞中BTLA表达升高。BTLA的上调会导致细胞功能障碍，而与黑色素瘤细胞上的HVEM交联可抑制T细胞扩增和IFN‐γ产生。最新研究显示，通过联合治疗手段，同时阻断 BTLA 和 PD-1 可以协同改善肿瘤抗原特异性 CD8+ T 细胞的扩增和增殖。基于以上研究，BTLA 正逐渐被认为是潜在的下一代癌症免疫治疗靶点。炎症性疾病BTLA对T细胞介导的炎症具有负调节作用。有体内研究证实，与野生型小鼠相比，BTLA-/-会延长小鼠的气道炎症，增强炎症细胞募集。此外，BTLA-/-小鼠表现出增强的DNFB介导的接触性超敏反应、CD8+ T细胞增殖和IFN-γ产生。而激动型抗BTLA抗体能逆转这些效应。自身免疫性疾病尽管BTLA-HVEM信号通路在自身免疫性疾病发病机制中的作用尚不清楚，但已有研究表明其在自身免疫预防中的重要性。体外研究证实，系统性红斑狼疮（SLE）患者表达BTLA的CD4+ T细胞减少。此外，BTLA阳性T细胞在疾病活动期显著下降。03在研格局目前海外市场礼来领跑，国内仅君实一家进入临床，但作为潜力靶点，已有众多企业开始布局该赛道。Tifcemalimab是一种人源化IgG4κ单克隆抗体，其在重链铰链区228号丝氨酸蛋白位点引入了脯氨酸（S228P）点突变，增加抗体的稳定性，减少IgG4可变区置换。在22年12月美国血液学会（ASH）年会上公布了Tifcemalimab治疗复发或难治性淋巴瘤的最新研究结果。单药治疗组中（n=25），1例PR和7例SD；与PD-1联合治疗组中（n=28），ORR达39.3%，DCR达85.7%，其中1例CR、10例PR和13例SD。靶病灶随时间变化情况和最佳缓解情况（联合治疗）小结：2002年，陈列平发表文章，证明了PD1/PDL1在肿瘤治疗中的价值。十年过去了，PD-1已成为火爆至极的靶点，而HVEM-BTLA机制发现相对较晚，一直处于冷门行列，但其作为单药和与PD-1联用的潜力药物，已开始入局免疫检查点的下一个十年。扫码查询现货细胞系参考：1.Doi: 10.3390/ijms23073529.2.Doi: 10.3389/fimmu.2021.654960.3.https://www.bio-techne.com/reagents/proteins/btla-cd160-hvem-proteins.4.https://xueqiu.com/5014087220/237609439.往期推荐盘点2022全球药企研发费用TOP10国外主要ADC技术梳理（下）小核酸药市场概览点击下方“药研网”，关注更多精彩内容

免疫疗法细胞疗法临床终止